Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 217 - 224 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC1682 | KN-92 phosphate |
|
Inactive analog of the CaM kinase II inhibitor KN 93. Potassium channel (K<sub>v</sub>1.2, 1.4, 1.5, 2.1, 3.2 and hERG) blocker<em> in vitro</em>.
|
|
| BCC1683 | KN-93 |
|
Potent, cell permeable inhibitor of CaM kinase II (IC<sub>50</sub> = 0.37 <span class='symbol'>μ</span>M). Also a direct extracellular open channel blocker of voltage-gated potassium channels (IC<sub>50</sub> = 307 nM for K<sub>V</sub>1.5) and abolishes IKr in ventricular myocytes (IC<sub>50</sub> = 102.6 nM) independently of CaM kinase II inhibition. Water soluble form also available.
|
|
| BCC1684 | Ko 143 |
|
Potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC<sub>90</sub> = 26 nM). Displays > 200-fold selectivity over P-gp and MRP-1 transporters. Increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. Inhibits ABCB1 and ABCC1 at higher concentrations. Rapidly metabolized in rat plasma.
|
|
| BCC1685 | KU14R |
|
Antagonist of the atypical imidazoline binding site (putative I<sub>3</sub> receptor) of pancreatic <span class='symbol'>β</span>-cells. Selectively blocks efaroxan-induced insulin secretion <em>in vitro</em> and <em>in vivo</em>.
|
|
| BCC1689 | Lck Inhibitor |
|
Potent inhibitor of lymphocyte specific kinase (Lck). IC<sub>50</sub> values are 0.007, 0.021, 0.042 and 0.20 <span class='symbol'>μ</span>M for Lck, Lyn, Src and Syk kinases respectively. Displays >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Inhibits T cell proliferation <em>in vitro</em> and inhibits arthritis in two <em>in vivo</em> models. Orally active.
|
|
| BCC1706 | LRRK2-IN-1 |
|
Potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2). Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC50 values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2.
|
|
| BCC1709 | Lucidin |
|
1. Lucidin and its derivatives are genotoxic, it is mutagenic at the hypoxanthine-guanine phosphoribosyl transferase gene locus.
|
|
| BCC1715 | LY 303511 |
|
Negative control compound with respect to LY 294002 PI 3-kinase inhibitory activity. Blocks voltage-gated potassium (K<sub>v</sub>) channels (IC<sub>50</sub> = 64.6 <span class='symbol'>μ</span>M) and inhibits IL-1<span class='symbol'>β</span>-stimulated NF-<span class='symbol'>κ</span>B activation, attenuating MCP-1 expression. Antiproliferative. Also inhibits the BET bromodomain proteins BRD2, BRD3 and BRD4.
|
|